H.R. 7867: Infant Formula Safety Modernization Act of 2026

This bill, known as the Infant Formula Safety Modernization Act of 2026, aims to improve the safety standards surrounding the manufacturing and testing of infant formula products in the United States. Key provisions include:

Enhanced Testing Requirements

The bill mandates that manufacturers of infant formula conduct standardized testing for pathogens and microorganisms within their manufacturing facilities and in the finished products. This includes:

• Updating good manufacturing practices to ensure testing is performed on both the facilities and the finished formula.
• Creating a list of specific pathogens, including clostridium botulinum, that must be tested for.
• Establishing recommended frequencies for environmental testing within the manufacturing facilities.
• Requiring manufacturers to notify the Secretary of any positive test results for specific pathogens within one business day.

Record Retention and Compliance Standards

Manufacturers will be required to maintain records of any positive test results, whether found in the formula or in the manufacturing facilities. The bill also directs the Commissioner of Food and Drugs to develop and enforce clear inspection and compliance standards applicable to all infant formula products regardless of their origin.

Congressional Notification

The bill establishes practices for notifying Congress about significant safety issues. Specifically, if the Secretary receives a notification of a positive test result for pathogens, they must inform the appropriate congressional committees within one business day. Similarly, if the FDA issues an inspection classification indicating action is needed, Congress must also be notified promptly.

Implementation Timeline

Regulations to enforce these new testing and notification requirements must be finalized within 90 days from the enactment of this bill.

Definitions of Testing Zones

The bill defines specific areas within the manufacturing facilities, termed “Zone 2” and “Zone 3,” which relate to contamination risks concerning where infant formula is manufactured.

Impact Scope

The bill's focus is on improving the safety and oversight of infant formula production in the U.S., potentially leading to better health outcomes for infants consuming these products.

Relevant Companies

• SYMN - This company produces infant formula and may need to adjust their manufacturing processes to comply with the newly mandated testing and safety requirements.
• PFIE - A manufacturer of infant formula that could be impacted by the new compliance standards and inspection requirements detailed in the bill.
• SIMO - Involved in infant product manufacturing, this company may be subject to the standards set by the new regulations for safety testing and notifications.